MEDTOX SCIENTIFIC INC
10-Q, EX-27, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: MEDTOX SCIENTIFIC INC, 10-Q, 2000-11-14
Next: CONCORD EFS INC, 10-Q, 2000-11-14



<TABLE> <S> <C>


<ARTICLE>                                      5

<MULTIPLIER>                               1,000


<S>                                          <C>
<PERIOD-TYPE>                              9-MOS
<FISCAL-YEAR-END>                     DEC-31-2000
<PERIOD-END>                          SEP-30-2000
<CASH>                                         0
<SECURITIES>                                   0
<RECEIVABLES>                             10,474
<ALLOWANCES>                                 335
<INVENTORY>                                3,083
<CURRENT-ASSETS>                          13,813
<PP&E>                                    17,451
<DEPRECIATION>                            12,301
<TOTAL-ASSETS>                            31,767
<CURRENT-LIABILITIES>                      9,134
<BONDS>                                        0
                          0
                                    0
<COMMON>                                     526
<OTHER-SE>                                18,678
<TOTAL-LIABILITY-AND-EQUITY>              31,767
<SALES>                                   32,565
<TOTAL-REVENUES>                          32,565
<CGS>                                     19,857
<TOTAL-COSTS>                             31,310
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                           751
<INCOME-PRETAX>                            1,255
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                        1,255
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                               1,255
<EPS-BASIC>                                 0.42
<EPS-DILUTED>                               0.39



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission